With a patent filed in the United States, Butantan Institute will be able to export the vaccine technology to the Northern Hemisphere, that is currently facing dengue cases. In this way, the project will gain even more international visibility.

According to the Institute’s director, the vaccine development started in 2007, but the result of the patent came after almost a decade in 2015. Having already passed through the steps that analyze its safety, conducted with about 14,000 volunteers, the vaccine developed is in its third phase to verify its effectiveness. The director says that the research is already becoming a product and hopes that by 2020 it will be available to the population.

The success of the vaccine also comes from the fact that around R$ 300 million (around US$70 million) was invested by the public sector. The importance of this type of investment is highlighted by the Institute, since there are many patent registrations in Brazil that cannot evolve due to lack of financial resources.

*translated and adapted from Sao Paulo University webpage. The original publication can be found here